Regeneron Pharmaceuticals, Inc. has announced it will release its financial and operating results for the third quarter of 2025 on October 28, prior to the opening of U.S. financial markets. The company also plans to hold a conference call and webcast at 8:30 AM Eastern Time that day.
According to Regeneron, participants can access the live conference call through a webcast available on the Investors and Media section of the company’s website at https://investor.regeneron.com. Those wishing to join by telephone are required to register in advance, after which they will receive an email with instructions, including a dial-in number, unique passcode, and registrant ID. The company states that both a replay and transcript of the event will be accessible on its website for at least 30 days.
Regeneron describes itself as a biotechnology firm focused on inventing, developing, and commercializing medicines for serious diseases. The company notes that many of its approved treatments and pipeline candidates originated from its own laboratories. Its portfolio targets conditions such as eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological disorders, hematologic conditions, infectious diseases, and rare diseases.
The company highlights its proprietary technologies like VelociSuite for producing fully human antibodies and bispecific antibodies. It also points to efforts in genetic research through the Regeneron Genetics Center and development of genetic medicine platforms aimed at identifying new treatment targets.
Further information about Regeneron is available on its website or through its social media channels.
“
